Detalles de la búsqueda
1.
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Invest New Drugs
; 32(5): 955-68, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942404
2.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Oncotarget
; 11(17): 1478-1492, 2020 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391118
3.
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Oncotarget
; 11(3): 216-236, 2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076484
4.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
5.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep
; 22(11): 2978-2994, 2018 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539425
6.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer Cell
; 32(6): 761-776.e6, 2017 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232554
7.
A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Mol Cancer Ther
; 14(11): 2463-72, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26304237
Resultados
1 -
7
de 7
1
Próxima >
>>